DYAI — Dyadic International Share News
0.000.00%
Last trade - 00:00- $15.99m
- $17.91m
- $3.09m
Brief: Dyadic International And Proliant Health And Biologicals Announce Recombinant Albumin Development And Commercialization Partnership
Brief: Dyadic International Files Prospectus Relates To Offer And Sale Of Up To 3.4 Mln Shares
Dyadic International Inc reports results for the quarter ended in December - Earnings Summary
Brief: Dyadic International, Inc. FY EPS USD -0.24
Brief: Biotech Firm Dyadic Chairman Michael Tarnok To Step Down
Dyadic International Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Dyadic Announces Strategic Partnership Agreement
Brief: Dyadic International Announces Collaboration With Israel Institute For Biological Research
Brief: Dyadic Announces Research And Development Collaboration Agreement With Global Biopharmaceutical Company
Brief: Dyadic Announces Top-Line Results From Its Successful Phase 1 Clinical Trial For A First-In-Human Filamentous Fungal-Based Vaccine Candidate
Brief: Dyadic Appoints Doug Pace To Its Executive Leadership Team
Brief: Dyadic - On Oct 2, Janssen Provided Written Notice To Dyadic That It Has Decided To Wind Down Collaboration
Brief: Dyadic’S C1 Platform Selected By The Vaccine And Immunotherapy Center (“VIC”) At Massachusetts General Hospital As Part Of Vic’S $5.88 Million Award By U.S. DoD
Dyadic International Inc reports results for the quarter ended in June - Earnings Summary
Brief: Dyadic International Inc Files For Stock Shelf Of Up To $50 Mln - SEC Filing
Dyadic International Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Dyadic Provides Phase 1 Clinical Trial Update For Its RBD Vaccine Candidate
Brief: Dyadic Announced An MoU With Bangladesh’s State-Owned Pharmaceutical Company To Facilitate Biopharmaceutical Research And Biomanufacturing Capacity
Brief: Dyadic Announces First Quarter 2023 Financial Results And Highlights Recent Company Progress